Stand Up To Cancer

share / bookmark page

Stand Up To Cancer

Stand Up To Cancer (SU2C), the Entertainment Industry Foundation's charitable initiative supporting groundbreaking research aimed at getting new cancer treatments to patients in an accelerated timeframe, has awarded the first round of three-year grants — that total $73.6 million -- to five multi-disciplinary, multi-institutional research Dream Teams.

Dream Teams:

"Bringing Epigenetic Therapy to the Forefront of Cancer Management"

Leader: Stephen B. Baylin, M.D., deputy director, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Baltimore, MD)
Co-Leader: Peter A. Jones, Ph.D., distinguished professor of urology, biochemistry and molecular biology, University of Southern California (Los Angeles, CA)
Steven Belinsky, Ph.D., director, Lung Cancer Program, Lovelace Respiratory Research Institute
Jean-Pierre Issa, M.D., professor, department of leukemia, University of Texas M.D. Anderson Cancer Center (Houston, TX)
Nancy Davidson, M.D., director, University of Pittsburgh Cancer Institute and UPMC Cancer Centers (Pittsburgh, PA)
Advocates:
Diana Chimgos, cancer patient advocate and chairman, Cancer Survivorship Advisory Council, USC-Norris Comprehensive Cancer Center (Los Angeles, CA)
Lillie Shockney, R.N., B.S., MAS, administrative director, Avon Foundation Breast Center, Johns Hopkins (Baltimore, MD)

“Targeting the PI3K Pathway in Women’s Cancers”
Leader: Lewis C. Cantley, Ph.D., chief, division of signal transduction, Beth Israel Deaconess Medical Center (Boston, MA)
Co-Leader: Charles L. Sawyers, M.D., director, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center (New York NY)
Co-Leader: Gordon B. Mills, M.D., Ph.D., chair, department of systems biology, University of Texas M.D. Anderson Cancer Center (Houston, TX)
Thomas M. Roberts, Ph.D., co-chair, department of cancer biology, Dana-Farber Cancer Institute (Boston, MA)
Carlos Arteaga, M.D., director, Vanderbilt Breast Cancer Program, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University (Nashville, TN)
José Baselga, M.D., chairman and professor of medicine, Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital (Barcelona, Spain)
Ramon Parsons, M.D., Ph.D., Avon Professor of pathology and medicine, Institute for Cancer Genetics and the Herbert Irving Comprehensive Cancer Center, Columbia University (New York, NY)
Advocates:
Sarah Weiss, advocate, Dana-Farber Cancer Institute (Boston, MA)
Judi Hirshfield-Bartek, R.N., M.S., O.C.N., clinical nurse specialist, Beth Israel Deaconess Medical Center, Breast Care Center (Boston, MA)
Elizabeth Frank, lead patient advocate, Dana-Farber Cancer Institute/Harvard Cancer Center, Breast SPORE (Boston, MA)
Ruth Fax, patient advocate, Dana-Farber Cancer Institute, Breast Cancer SPORE (Boston, MA)
Patricia Lee, Vanderbilt-Ingram Cancer Center (Nashville, TN)
Don Listwin, Canary Foundation (Palo Alto, CA)
Jane Perlmutter, Ph.D., University of Texas M. D. Anderson Cancer Center (Houston, TX)
Janet Price, Columbia University/Herbert Irving Comprehensive Cancer Center (New York, NY)

“An Integrated Approach to Targeting Molecular Breast Cancer Molecular Subtypes and Their “Resistance” Phenotypes”
Leader: Joe W. Gray, Ph.D., director, Life Sciences Division, Lawrence Berkeley National Laboratory (Berkeley, CA)
Leader: Dennis J. Slamon, M.D., Ph.D., director of clinical/translational research at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center (Los Angeles, CA)
Arul Chinnaiyan, M.D., Ph.D., director, Michigan Center for Translational Pathology, University of Michigan (Ann Arbor, MI)
Peter Sorger, Ph.D., professor, Systems Biology, Harvard Medical School (Boston, MA)
David Haussler, Ph.D., investigator, Howard Hughes Medical Institute (Santa Cruz, CA)
Terry Speed, Ph.D., professor, department of statistics, University of California, Berkeley (Berkeley, CA)
Zena Werb, Ph.D., professor and vice-chair, department of anatomy, Helen Diller Comprehensive Cancer Center (San Francisco, CA)
Professor Alan Ashworth FRS, Ph.D., director, Breakthrough Breast Cancer, The Institute of Cancer Research, London, UK (London, UK)
Joan Brugge, Ph.D., professor and chair, Cell Biology, Harvard Medical School (Boston, MA)
Gregory Hannon, Ph.D., professor, Watson School of Biological Sciences, Cold Spring Harbor Laboratory (Cold Spring Harbor, NY)
V. Craig Jordan OBE, Ph.D., D.Sc., scientific director, Vincent T. Lombardi Comprehensive Cancer Center, Georgetown University ( effective July 1) (Washington, DC)
C. Kent Osborne, M.D., director, Dan L. Duncan Cancer Center and Lester and Sue Smith Breast Center, Baylor College of Medicine (Houston, TX)
Max Wicha, M.D., director, University of Michigan Comprehensive Cancer Center (Ann Arbor, MI)
Advocates:
Janice Barlow, executive director, Zero Breast Cancer (San Rafael, CA)
Cindy Geoghegan, patient advocate, NCI Specialized Programs of Research Excellences (SPORES).
Ellen Stoval, National Coalition for Cancer Survivorship (Washington, DC)
Fran M. Visco, Esq., National Breast Cancer Coalition (Washington, DC)

“Bioengineering and Clinical Applications of Circulating Tumor Cells Chip”
Leader: Daniel A. Haber, M.D., Ph.D., director, Massachusetts General Hospital Cancer Center (Boston, MA)
Co-Leader: Mehmet Toner, Ph.D., professor, biomedical engineering, Massachusetts General Hospital, Harvard Medical School (Boston, MA)
Sangeeta N. Bhatia, M.D., Ph.D., professor of HST/EECS, Massachusetts Institute of Technology
(HST/EECS=health sciences and technology/electrical engineering and computer science) (Boston, MA)
Bruce E. Johnson, M.D., professor of medicine, Dana-Farber Cancer Institute (Boston, MA)
Mark G. Kris, M.D., chief of thoracic oncology service, Memorial Sloan-Kettering Cancer Center (New York, NY)
Roy S. Herbst, M.D., Ph.D., professor of medicine and cancer biology, University of Texas M. D. Anderson Cancer Center (Houston, TX)
Advocates:
Jeanie Ungerleider, Ph.D., L.I.C.S.W., director, psychological services, Boston IVF (Brookline, MA)
Becky Douglas, founder, Douglass Charitable Foundation

“Cutting off the Fuel Supply: A New Approach to the Treatment of Pancreatic Cancer”
Leader: Craig B. Thompson, M.D., director, Abramson Cancer Center, University of Pennsylvania (Philadelphia, PA)
Leader: Daniel D. Von Hoff, M.D., F.A.C.P., senior investigator and physician in chief, Translational Genomics Research Institute (TGen) (Phoenix, AZ)
Chi Dang, M.D., Ph.D., vice dean for research, Johns Hopkins University School of Medicine
Geoffrey Wahl, Ph.D., past president, AACR (Baltimore, MD)
Joshua Rabinowitz, M.D., Ph.D., assistant professor of chemistry and integrative genomics, Princeton University (Princeton, NJ)
Advocates:
Barton Kamen, scientific director of the Leukemia and Lymphoma Society (White Plains, NY)
Howard Young
Randall Katz
Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network (El Segundo, CA)

Innovative Grants:

Stand Up ToCancer (SU2C) has also awarded $9.68 million to support high-risk/high-reward cancer research conducted by 13 young scientists. Over a three-year period, each investigator will receive a total of up to $750,000 as part of SU2C’s Innovative Research Grants program, which supports the next generation of cancer research leaders.

The projects funded all represent new approaches to the most important and challenging problems facing cancer researchers today. They address a wide range of cancer types and organ sites, including lung, ovarian and breast cancers, as well as leukemia and lymphomas. Some projects focus on developing improved therapies for difficult to treat cancers that affect children and young adults, including Ewing sarcoma and rhabdoid tumors. All the projects have the potential to significantly advance the identification of the complex mechanisms that cause cancers to occur and spread; to lead to the development of a new generation of targeted treatments; and to improve the methods of diagnosing cancers and monitoring the effects of treatment.

The 13 Stand Up To Cancer Innovative Research Grant recipients for 2009 are:

Fernando D. Camargo, Ph.D., Children’s Hospital Boston: An Emerging Tumor Suppressor Pathway in Human Cancer

Elizabeth R. Lawlor, M.D., Ph.D., Childrens Hospital Los Angeles: Modeling Ewing Tumor Initiation in Human Neural Crest Stem Cells

Matthew Levy, Ph.D., Albert Einstein College of Medicine of Yeshiva University: Cancer Cell Specific, Self-delivering Pro-drugs

Markus Müschen, M.D., Childrens Hospital Los Angeles: Targeted Inhibition of BCL6 for Leukemia Stem Cell Eradication

William Pao, M.D., Ph.D., Vanderbilt-Ingram Cancer Center/Vanderbilt University: Identifying Solid Tumor Kinase Fusions via Exon Capture and 454 Sequencing

Charles M. Roberts, M.D., Ph.D., Dana-Farber Cancer Institute: Therapeutically Targeting the Epigenome in Aggressive Pediatric Cancers

Rajat Rohatgi, M.D., Ph.D., Stanford University: Endogenous Small Molecules that Regulate Signaling Pathways in Cancer Cells

José M. Silva, Ph.D., Columbia University Medical Center: Genetic Approaches for Next Generation of Breast Cancer Tailored Therapies

Kimberly Stegmaier, M.D., Dana-Farber Cancer Institute: Modulating Transcription Factor Abnormalities in Pediatric Cancer

Muneesh Tewari, M.D., Ph.D., Fred Hutchinson Cancer Research Center: Noninvasive Molecular Profiling of Cancer via Tumor-derived Microparticles

Loren D. Walensky, M.D., Ph.D., Dana-Farber Cancer Institute: A Transformative Technology to Capture and Drug New Cancer Targets

David M. Weinstock, M.D., Dana-Farber Cancer Institute: Functional Oncogene Identification

Hang Yin, Ph.D., University of Colorado at Boulder: Probing EBV-LMP-1’s Transmembrane Activation Domain with Synthetic Peptide